HUITAI Biomedicine, located in Chengdu city, the southwest of China, founded in 2017, is an early clinical stage biopharmaceutical company. HUITAI is developing novel treatments for fibrotic diseases by creating small polypeptide therapeutics with a large safety margin. HUITAI is developing novel therapeutics to address the most severe and difficult-to-treat fibrotic conditions of the lung, liver, kidney and other organs. All of our products possess the purpose of significantly increasing the benefit-risk profile in patients, which is crucial to anti-fibrotic treatment. The company is financed by its own founders and executives whose loved family members died because of pulmonary fibrosis.